Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/body-dysmorphic-disorder-inhibiteurs-de-la-recapture-de-la-s-rotonine-n0gdRZUxQ7
References (16)
-
G. Perugi, D. Giannotti, S. Vaio, F. Frare, M. Saettoni, G. Cassano (1996)
Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia)International Clinical Psychopharmacology, 11
-
K. Phillips, R. Albertini, S. Rasmussen (2002)
A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.Archives of general psychiatry, 59 4
-
D. Stein, L. Roux, C. Bouwer, B. Heerden (1998)
Is olfactory reference syndrome an obsessive-compulsive spectrum disorder?: two cases and a discussion.The Journal of neuropsychiatry and clinical neurosciences, 10 1
-
K. Phillips (1996)
Pharmacologic treatment of body dysmorphic disorder.Psychopharmacology bulletin, 32 4
-
T. Nagata, I. Vliet, H. Yamada, Kouhei Kataoka, T. Iketani, N. Kiriike (2006)
An open trial of paroxetine for the “offensive subtype” of taijin kyofusho and social anxiety disorderDepression and Anxiety, 23
-
F. Gatti, L. Bellini, M. Gasperini, Jorge Pérez, R. Zanardi, E. Smeraldi (1996)
Fluvoxamine alone in the treatment of delusional depression.American Journal of Psychiatry, 153
-
K. Phillips (1996)
The broken mirror : understanding and treating body dysmorphic disorder -
Katharine Phillips, M. Dwight, Susan McElroy (1998)
Efficacy and safety of fluvoxamine in body dysmorphic disorder.The Journal of clinical psychiatry, 59 4
-
J. Tignol (2006)
Les défauts physiques imaginaires -
E. Hollander, M. Liebowitz, R. Winchel, Almuth Klumker, D. Klein (1989)
Treatment of body-dysmorphic disorder with serotonin reuptake blockers.The American journal of psychiatry, 146 6
-
E. Hollander, A. Allen, Jee Kwon, B. Aronowitz, J. Schmeidler, Cheryl Wong, D. Simeon (1999)
Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness.Archives of general psychiatry, 56 11
-
R. Zanardi, L. Franchini, M. Gasperini, J. Perez, E. Smeraldi (1996)
Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression.The American journal of psychiatry, 153 12
-
K. Phillips (1991)
Body dysmorphic disorder: the distress of imagined ugliness.The American journal of psychiatry, 148 9
-
K. Phillips, R. Albertini, J. Siniscalchi, A. Khan, Marshall Robinson (2001)
Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study.The Journal of clinical psychiatry, 62 9
-
K. Phillips, S. McElroy (1993)
Insight, overvalued ideation, and delusional thinking in body dysmorphic disorder: theoretical and treatment implications.The Journal of nervous and mental disease, 181 11
-
F. Quitkin, A. Rifkin, D. Klein (1978)
Imipramine response in deluded depressive patients.The American journal of psychiatry, 135 7
- Publisher
- Springer Journals
- Copyright
- Copyright © 2007 by Springer Verlag France
- Subject
- Medicine & Public Health; Behavioral Therapy ; Psychoanalysis ; Psychotherapy ; Psychopharmacology; Neuropsychology; Psychiatry
- ISSN
- 1639-8319
- eISSN
- 1955-2351
- DOI
- 10.1007/s11836-007-0036-9
- Publisher site
- See Article on Publisher Site
Abstract
Le body dysmorphic disorder (BDD) n’est devenu une maladie autonome qu’en 1987, après avoir été considéré tantôt comme un trouble obsessionnel, tantôt comme un trouble délirant. Néanmoins, il ne répondait pas aux neuroleptiques. La démonstration, dans les années 1990, de l’efficacité des inhibiteurs de la recapture de la sérotonine (IRS), tant dans les formes délirantes que non délirantes du BDD, a représenté un progrès thérapeutique remarquable, encore trop peu appliqué. Elle fait aussi se poser la question de l’existence de deux sortes de délires, certains sensibles aux neuroleptiques, les autres aux IRS.
Journal
PSN – Springer Journals
Published: Oct 9, 2007